Axsome Therapeutics Reports Q1 Revenue Growth of 57% YoY and FDA Approval for Auvelity in Alzheimer's Agitation
Axsome Therapeutics reported first-quarter revenue growth of $191 million, a 57% increase year-over-year, driven by strong performance from its products Auvelity ($153.2M) and Sunosi ($33.9M). The company received FDA approval for Auvelity to treat agitation in Alzheimer's disease and plans a June commercial launch with an expanded salesforce of 630 reps.
Tickers: $AXSM
Topics: biotech FDA approval neuroscience pipeline revenue growth